Agios Pharmaceuticals AGIO EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Agios Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's EBITDA margin?
- Agios Pharmaceuticals (AGIO) reported EBITDA margin of -712% in Q1 2026.
- How has Agios Pharmaceuticals's EBITDA margin changed year-over-year?
- Agios Pharmaceuticals's EBITDA margin increased by 39.3% year-over-year, from -1,173.8% to -712%.
- What is the long-term trend for Agios Pharmaceuticals's EBITDA margin?
- Over 4 years (2020 to 2025), Agios Pharmaceuticals's EBITDA margin has grown at a 51.5% compound annual growth rate (CAGR), from -164% to -864.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.